"Cannabis Green Wave" versus "Nicotine Freeze": the regulatory paradox of cannabis liberalization and nicotine prohibition.

Farsalinos K. · Harm reduction journal · 2026

**Background & Methods** This is a narrative review article examining the regulatory paradox between cannabis liberalization and nicotine prohibition across contemporary psychoactive substance policies. The author analyzes toxicological, sociological, and bioethical frameworks to interrogate inconsistencies in how these two substances are regulated despite similar harm profiles when delivered through non-combustible routes. **Key Findings** - Regulatory asymmetry exists whereby cannabis products (smokeable, edible, and flavored formulations) receive progressive liberalization under harm-reduction and social-equity frameworks, while non-combustible nicotine alternatives face neo-prohibitionist restrictions despite lower toxicological risk profiles stemming primarily from combustion rather than the active compounds themselves. - Neurocognitive and youth-protection standards are applied inconsistently: the "gateway theory" and flavor restrictions aggressively restrict nicotine products, while cannabis—which carries documented risks of cognitive impairment and psychosis with heavy use—increasingly incorporates youth-appealing flavored products with minimal regulatory resistance. - Current regulatory frameworks enforce a moral hierarchy that prioritizes "cognitive liberty" arguments for cannabis legalization while simultaneously applying "hard paternalism" to nicotine users, denying smokers access to harm-reduction substitutes and inadvertently fostering unregulated black markets through prohibition mechanisms that policymakers have otherwise acknowledged as counterproductive. **Dosage & Administration** Not reported. **Safety & Adverse Effects** The review notes that primary harms from both substances appear linked to combustion rather than the active compounds (THC and nicotine). Cannabis use, particularly sustained heavy use, carries documented risks of cognitive impairment and psychosis. Nicotine is characterized as a non-intoxicating stimulant with potential cognitive benefits. Specific adverse effect profiles for individual formulations are not quantified. **Evidence Quality** This is a narrative review without systematic methodology, meta-analysis, or original data analysis. The evidence base derives from secondary literature synthesis and policy analysis rather than primary research. The work is conceptually strong in identifying regulatory inconsistencies but lacks quantitative comparative harm data. Publication in 2026 in *Harm Reduction Journal* reflects contemporary policy discourse; however, the argument structure is primarily philosophical and evidence-based rather than epidemiologically rigorous, limiting the strength of causal conclusions about regulatory outcomes.

More recent cannabis research